In 240 participants with hyperandrogenic PCOS and BMI 25-48 randomised to low-dose COCPs, metformin or both for 24 weeks, metabolic syndrome prevalence did not differ (28.8%, 26.2%, 28.6%; p=0.26); diarrhoea was common with metformin.
RCTn = 240
Dokras et al. Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial